The current debate on disclosure thresholds obscures the much larger question of why doctors need to receive “tea and biscuits” from pharmaceutical companies at all, write Wendy Lipworth and Ian Kerridge.
Scandals implicating pharmaceutical companies show we need better strategies if “corporate integrity” is to mean anything in the globalised medicine market, write Wendy Lipworth and Ian Kerridge.
It’s in the public interest to establish consumer groups' independence and to expect their relationships with industry to be both disclosed and appropriately managed, write Wendy Lipworth and Ian Kerrige.
